Brief: Satsuma Says New Phase 3 Trial For Migraine Product Candidate To Begin Mid-2021
01/03/2021 12:53
March 1 (Reuters) - Satsuma Pharmaceuticals Inc STSA.O :
* SATSUMA PHARMACEUTICALS - NEW STS101 PHASE 3 EFFICACY
TRIAL
PLANNED TO BEGIN MID-2021 WITH TOPLINE RESULTS EXPECTED 2H 2022
* SATSUMA PHARMACEUTICALS INC - PROCEEDS FROM $80 MILLION
PRIVATE
PLACEMENT, CASH EXPECTED TO FUND OPERATIONS INTO 2H 2023
Source text for Eikon: ID:nGNX9ZWM75
Further company coverage: STSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Satsuma Pharmaceuticals
See all newsBrief: Satsuma Pharmaceuticals Announces FDA Acceptance Of 505(B)(2) NDA For Sts101, A Novel And Investigational Dihydroergotamine Nasal Powder Product For The Acute Treatment Of Migraine
Commencement Of Tender Offer For Satsuma Pharmaceuticals, Inc In U.S.
Brief: Satsuma Pharmaceuticals Says Received Letter Notifying Co Regained Compliance With Nasdaq
U.S. STOCKS ON THE MOVE-Alphabet Inc, BlackRock, Moderna
Satsuma Pharma soars on buyout deal from Japan's Shin Nippon